Phaseline

Companies › Jiangsu Topcel-KH Pharmaceutical

Jiangsu Topcel-KH Pharmaceutical: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 3; Oncology, Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Human TH-SC01 cell injection
Umbilical cord-derived allogeneic stem cell therapy
–Phase 3Crohn's DiseaseDec 2026
Anti-PD1 armored CD19 CAR-T cells
Anti-PD1 armored CD19 CAR-T cell therapy
CD19, PDCD1Phase 1Diffuse Large B Cell LymphomaJan 2027
BAFF-R CAR-T cells
BAFF receptor-targeted chimeric antigen receptor T-cell therapy
TNFRSF13CPhase 1B-cell LymphomaJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06925594Human TH-SC01 cell injectionPhase 3Crohn's DiseaseImmunologyDec 2026
NCT07368270Anti-PD1 armored CD19 CAR-T cellsPhase 1Diffuse Large B Cell LymphomaOncologyJan 2027
NCT07369492BAFF-R CAR-T cellsPhase 1B-cell LymphomaOncologyJan 2027

Targets

CD19 (1) PDCD1 (1) TNFRSF13C (1)

Companies with the same targets

Gilead Sciences Bristol-Myers Squibb AstraZeneca Chongqing Precision Biotech Akeso Allogene Therapeutics Amgen Miltenyi Biomedicine Novartis Roche

Companies built like this

Beijing Yongtai Ruike Biotechnology Company iCell Gene Therapeutics Hebei Senlang Biotechnology PersonGen BioTherapeutics (Suzhou) Shanghai Ming Ju Biotechnology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.